Yearly Archives: 2022

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Nov 15, 2022, 07:30 ET ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a…

Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Oct 18, 2022, 07:30 ET Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced…

Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment

Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment Over-subscribed round to support Phase2a clinical trial in atopic dermatitis ANNAPOLIS, MD, September 15, 2022 – Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it is has closed a Series A financing round of approximately $3.3…